Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.Kevin Kalinsky, Seth A. Wander, Erika Hamilton et al.|Journal of Clinical Oncology|2024Cited by 75
Caveolin-1 Modulates Docetaxel-Induced Cell Death in Breast Cancer Cell Subtypes through Different MechanismsJin-Ho Kang, Kyong Hwa Park|Cancer Research and Treatment|2015Cited by 30
A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironmentJin-Ho Kang, Kyong Hwa Park|Scientific Reports|2019Cited by 27